• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

    8/29/22 12:28:20 PM ET
    $DNAA
    Get the next $DNAA alert in real time by email
    SC 13G 1 a082922a.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
    (Amendment No. ___)*
    Under the Securities Exchange Act of 1934



    Akili, Inc.
    (Name of Issuer)
    Common Stock, par value $0.0001 per share
    (Titles of Class of Securities)
    00974B107
    (CUSIP Number)
    August 19, 2022
    (Date of Event Which Requires Filing of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     





    1
    NAME OF REPORTING PERSON
     
    Aaron Cowen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)  ☐        (b)  ☐
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,627,000 (1)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,627,000 (1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,627,000 (1)
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    7.8% (2)
    12
    TYPE OF REPORTING PERSON
     
    IN

    (1)
    Averill Master Fund, Ltd. is the record holder of 3,540,000 shares of Issuer Common Stock (as defined herein) reported herein.  SVAV Sponsor I, LLC is the record holder of 3,087,000 shares of Issuer Common Stock reported herein.  See Item 2(a) herein.
    (2)
    Calculated based upon 85,395,207 shares of Issuer Common Stock reported to be outstanding as of August 19, 2022, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 23, 2022.




    Explanatory Note:
    This statement on Schedule 13G (“Schedule 13G”) is filed with respect to the Issuer Common Stock (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below).  On August 19, 2022, the SPAC (as defined in Item 1(a) below) consummated the business combination (the “Business Combination”) contemplated by that certain Agreement and Plan of Merger, dated as of January 26, 2022, by and among the SPAC, Karibu Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of the SPAC, and Akili Interactive Labs, Inc., a Delaware corporation.  Concurrently with the consummation of the Business Combination, SCS Sponsor I LLC (“SCS Sponsor I”) distributed for no consideration 6,860,000 shares of Issuer Common Stock to its two members, SVAV Sponsor I, LLC and SC SPAC Holdings LLC, pro rata in accordance with their respective interests (the “Distribution), such that following the Distribution, SCS Sponsor I ceased to be the record holder of such shares.  On August 26, 2022, SCS Sponsor I and the other reporting persons named therein filed Amendment No. 1 to Schedule 13G, amending the statement on Schedule 13G filed on February 9, 2022 by SCS Sponsor I and the other reporting persons named therein to disclose that the reporting persons named therein have ceased to be the beneficial owner of more than five percent of any class of equity security (as defined in Rule 13d-1(i)) of the Issuer as a result of their direct or indirect interests in SCS Sponsor I.  The Reporting Person is filing this statement on Schedule 13G to reflect the beneficial ownership of the shares of the Issuer following the Distribution, together with the other shares of Issuer Common Stock that may be deemed to be beneficially owned by the Reporting Person as of the date of this filing.
    Item 1(a).
    Name of Issuer:
    Akili, Inc. (formerly known as Social Capital Suvretta Holdings Corp. I), a Delaware corporation (the “Issuer” and, prior to the consummation of the Business Combination, the “SPAC”).
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    125 Broad Street, Fifth Floor, Boston, Massachusetts 02110
    Item 2(a).
    Name of Person Filing:
    This Schedule 13G is filed by Aaron Cowen, an individual (“Mr. Cowen” or the “Reporting Person”).  Averill Master Fund, Ltd., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Averill Fund”), is the record holder of 3,540,000 shares of Issuer Common Stock reported herein. SVAV Sponsor I, LLC, a Delaware limited liability company (“SVAV”), is the record holder of 3,087,000 shares of Issuer Common Stock reported herein.  Mr. Cowen may be deemed to control Suvretta Capital Management, LLC, the investment manager of the Averill Fund, and therefore may be deemed to beneficially own the shares of Issuer Common Stock held by the Averill Fund.  Mr. Cowen may be deemed to control SVAV and therefore may be deemed to beneficially own the shares of Issuer Common Stock held by SVAV. 
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:
    The principal business address of Mr. Cowen is as follows:
    c/o Suvretta Capital Management, LLC
    540 Madison Avenue, 7th Floor,
    New York, New York 10022
    Item 2(c).
    Citizenship:
    See response to Item 4 on cover page.
    Item 2(d).
    Titles of Classes of Securities:
    Common stock, par value $0.0001 per share (“Issuer Common Stock”).
    Item 2(e).
    CUSIP Number:
    The shares of Issuer Common Stock CUSIP Number is 00974B107.
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)  ☐ Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).

    (b)  ☐ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

    (c)  ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

    (d)  ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e)  ☐ Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    (f)  ☐ Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

    (g)  ☐ Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

    (h)  ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)  ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

    (j)  ☐ Non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

    (k)  ☐ Group in accordance with §240.13d-1(b)(1)(ii)(K).
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:  ______________ .
    Item 4.
    Ownership
    (a) Amount beneficially owned:
    See response to Item 9 on cover page.
    (b) Percent of class:
    See responses to Item 11 on cover page.
    (c) Number of shares as to which such person has:
    (i) Sole power to vote or to direct the vote:
    See response to Item 5 on cover page.
    (ii) Shared power to vote or to direct the vote:
    See response to Item 6 on cover page.
    (iii) Sole power to dispose or to direct the disposition of:
    See response to Item 7 on cover page.
    (iv) Shared power to dispose or to direct the disposition of:
    See response to Item 8 on cover page.
    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    None.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    Not Applicable.
    Item 8.
    Identification and Classification of Members of the Group.
    Not Applicable.
    Item 9.
    Notice of Dissolution of Group.
    Not Applicable.
    Item 10.
    Certification.
    The Reporting Person hereby makes the following certification:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date:  August 29, 2022
    /s/ Aaron Cowen                               
    Aaron Cowen

    Get the next $DNAA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAA
    SEC Filings

    See more
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:13:45 AM ET
      $DNAA
    • Social Capital Suvretta Holdings Corp. I filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:06:32 AM ET
      $DNAA
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/5/23 7:21:42 AM ET
      $DNAA

    $DNAA
    Financials

    Live finance-specific insights

    See more
    • PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co

      1/26/22 7:02:00 AM ET
      $DNAA
      $GLS
      $KRTX
      $PRTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      Akili's leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depression Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in

      1/26/22 7:00:00 AM ET
      $DNAA

    $DNAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Jina Anil (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:14:59 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Ehlert Kenneth (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:15:13 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Martucci Walter Edward Ii (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:10:52 PM ET
      $DNAA

    $DNAA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

      8/25/22 2:07:00 AM ET
      $CPSR
      $DNAA
      $GLS
      $KRTX
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

      Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022. Akili raised more than $163 million from the

      8/19/22 5:25:00 PM ET
      $DNAA
    • PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

      New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta H

      7/11/22 7:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNAA
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where

      3/17/22 9:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader

      3/17/22 9:00:00 AM ET
      $DNAA

    $DNAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      1/20/23 6:27:44 AM ET
      $DNAA
    • SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. I

      SC 13D - Akili, Inc. (0001850266) (Subject)

      8/30/22 4:48:09 PM ET
      $DNAA
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      8/29/22 12:28:20 PM ET
      $DNAA